Apixaban
- PDF / 169,562 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 120 Downloads / 139 Views
1
S
Haematoma and intrauterine bleeding: 2 case reports In a study of 1847 patients, two patients [including one female patient; not all sexes stated; ages not stated] were described, of whom one patient developed haematoma and the female patient developed intrauterine bleeding during treatment with apixaban as a post-operative venous thromboembolism (VTE) prophylaxis. The patients underwent bariatric surgery. On post-operative day (POD) 3, the patients started receiving oral apixaban 2.5mg twice daily for 30 days as a VTE prophylaxis. The patients were discharged on apixaban therapy. On POD 11, one patient was re-admitted due to haematoma development near the remnant staple line and required IR drainage. The other female patient developed intrauterine bleeding, and was re-admitted [duration of treatments to reaction onsets and outcomes not stated]. Author comment: "Evaluate the incidence of bleeding complications and VTE events among patients receiving apixaban for VTE prophylaxis post-op." "[One] patient was readmitted POD11 . . . for a hematoma near the remnant staple line (required IR drainage), and another patient was readmitted for an intrauterine bleed." Borden B, et al. Could the novel oral anticoagulant apixaban be the answer for extended venous thromboembolism (VTE) prophylaxis following bariatric surgery? Surgery for Obesity and Related Diseases 15 (Suppl.): S14-S15, No. 10, Oct 2019 803432187 [abstract] - USA
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
